Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Ferrer Internacional S.A.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05866926CT.gov Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis | — | Terminated | — | — | — |
NCT05178810CT.gov Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Amyotrophic Lateral Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| fab122 (this asset) | Ferrer Internacional S.A. | P3 | CCC · 54 |
| Taurursodiol | Amylyx Pharmaceuticals Inc. | P3 | BBB |
| Tofersen | Biogen | P4 | BBB |
| Riluzole | AB Science | P4 | BB |
| Mexiletine | Bjorn Oskarsson, MD | P4 | BB |
| Diacetyl(N(4)-Methylthiosemicarbazonato) Copper (Ii) | Collaborative Medicinal Development Pty Limited | P2/3 | BB |
| mt-1186 | Tanabe Pharma Corporation | P3 | BB |
| Kns-760704 | Knopp Biosciences | P3 | BB |
| Mci-186 | Tanabe Pharma Corporation | P3 | BB |
+42 more in the Amyotrophic Lateral Sclerosis cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. fab122 in Amyotrophic Lateral Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fab122-amyotrophic-lateral-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →